



18 September 2023

Appointment of New Company Secretary and Chief Financial Officer

Melbourne, Australia, 18 September 2023: dorsaVi (ASX:DVL) (**dorsaVi** or the **Company**) is pleased to announce the appointment of Mr Aaron Chan as Chief Financial Officer replacing dorsaVi's current CFO Mr Troy Di Domenico, and the appointment of Mr Justin Mouchacca as Company Secretary, replacing the Company's current secretary Mr Brendan Case. Both appointments are effective as of 18th September 2023.

Mr Chan is Founder and Director at UpStart Advisory, a consulting firm that provides strategic advisory and finance function outsourcing services to private and listed companies. Mr Chan and his team at UpStart Advisory have been engaged on an outsourced basis to provide the function of a CFO.

Mr Chan is a certified Chartered Accountant and holds a Bachelor of Commerce (Accounting and Management) from the University of Melbourne. He brings over 15 years of experience to the role including positions as Manager in the Private Clients division of PricewaterhouseCoopers and as Head of Investment at Folk Capital, a boutique Venture Capital firm.

Mr Mouchacca is a Chartered Accountant and Fellow of the Governance Institute of Australia with over 16 years' experience in public company responsibilities including statutory, corporate governance and financial reporting requirements. Since July 2019, Mr Mouchacca has been principal of JM Corporate Services and has been appointed Company Secretary and Financial Officer for a number of entities listed on the ASX and unlisted public companies.

These appointments will allow dorsaVi to allocate resources towards achieving its growth objectives as the Company looks to execute on its expanded sales pipeline driven by increased demand for AI-enabled sensor technology.

Dr Andrew Ronchi, dorsaVi's Chief Executive Officer, commented:

"We are excited to work with Aaron and Justin and their respective teams at UpStart Advisory and JM Corporate Services. We look forward to leveraging Aaron's extensive financial management, reporting and forecasting experience as well as Justin's corporate governance and compliance expertise to help support our plans to scale. I would like to take this opportunity to thank both Troy and Brendan for their contribution to dorsaVi over their tenure. Troy's work has been instrumental in helping us to reduce our cost base and lay the foundations for future growth, while Brendan has been a key pillar in maintaining our corporate compliance and facilitating effective board communication. We wish Troy and Brendan all the very best for the future."

- ENDS -

For further information about dorsaVi, please contact:

Company

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
Email: ar@dorsavi.com

Investors

Dean Dribbin
Vesparum Capital
+61 3 8582 4800
Email: dorsavi@vesparum.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com